… EGFR mutation positive NSCLC. Methods: This study is an investigator initiated trial. Previously
untreated EGFR mutation … EGFR mutation (exon 19 deletion, Leu858Arg point mutation …

… third-generation EGFR-TKI selective for activating and T790M mutations while sparing
wild-type EGFR. In the Phase I part of a Phase I/II multicenter study of nazartinib in EGFR-mutant …

… Although these results suggest a potential role of EGFR-TKIs in patients with resected
EGFR-mutation-positive NSCLC, the effect of adjuvant therapy in clinical practice warrants further …

… or postoperative recurrent non-squamous NSCLC, with activating EGFR mutations (either …
EGFR mutations were screened by high-sensitivity EGFR gene mutation tests covered by …

… Given the encouraging results of a phase II study of dacomitinib in the first-line setting [24],
ARCHER 1050, a randomized, open-label phase III study of dacomitinib versus gefitinib, was …

… The safety data of afatinib from this interim analysis of a large-scale population of EGFR TKI-…
efficacy in patients with common and uncommon EGFR mutations. Data from larger patient …

… In 12 patients with confirmed HER2 mutations, we found no other known oncogenic drivers,
such as EGFR, KRAS, BRAF, MET, or MEK mutations or known driving gene rearrangements…

… of the EGFR gene. EGFR amplification is sometimes associated with mutations that are
believed … , independent of EGFR amplification and in a subgroup of patients with EGFR-amplified …

… We also did biochemical and haematological analyses and EGFR mutation testing, and we
assessed adverse events and baseline health-related quality of life (HRQoL). Before patients …

… This multicenter, open-label, phase Ib study expansion cohort … on EGFR-TKIs. Patients were
assigned to one of two cohorts by prior first- or second-generation or T790M-directed EGFR-…